



NEWS RELEASE

# CareDx Welcomes Initiatives from US Government to Support Transplant Care

2019-03-05

CMS initiative “Patients over Paperwork” aims to increase organ availability

BRISBANE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced support of the US Centers for Medicare and Medicaid Services (CMS) plan to increase access for kidney transplants alongside new payment structures for patients with kidney disease.

Over 700,000 people in the United States have kidney failure, and over 100,000 individuals are on the wait list for a kidney transplant. A key provision under the CMS initiative “Patients Over Paperwork” seeks to reduce burden on transplant centers that cause organs to go unused. CareDx applauds initiatives to increase the number of individuals who can receive transplantation.

CareDx is one of the sponsors of the National Kidney Foundation 2019 Kidney Patient Summit over March 4-5, 2019 where patients with kidney disease visit Capitol Hill. HHS Secretary Alex Azar spoke with these patients as part of this Summit to discuss the initiative.

“Transplant care represents a superior solution for patients, offering both lifestyle and cost benefits for the patient and healthcare system,” said Peter Maag, CEO of CareDx. “We are dedicated to the field of transplantation and welcome initiatives that support transplantation.”

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery,

development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: [www.CareDx.com](http://www.CareDx.com).

#### Forward Looking Statements

This press release includes forward-looking statements, including statements regarding the Company's support of the 2019 Kidney Patient Summit. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed by CareDx with the SEC on March 22, 2018 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx's actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

#### CONTACTS:

CareDx, Inc.  
Sasha King  
Chief Commercial Officer  
415-287-2393  
[sking@caresdx.com](mailto:sking@caresdx.com)

Investor Relations  
David Clair  
Integrated Corporate Relations, Inc.  
646-277-1266  
[david.clair@icrinc.com](mailto:david.clair@icrinc.com)

Source: CareDx, Inc.